Li-kun Chen: Clinical Trials

4 trials sponsored by Li-kun Chen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 unknown. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1

Follow Li-kun Chen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab - Lung Cancer
Phase 2Not yet recruitingLi-kun Chen502025-10-012025-09-29
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Administration of Vorolanib - Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer
Phase 2RecruitingLi-kun Chen322024-12-012024-12-11
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
The treatment regimen is Befotertinib combined with Bevacizumab. - Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer
Phase 2Active not recruitingLi-kun Chen702024-09-042026-10-21
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Anlotinib - Non-small Cell Lung Cancer, Brain Metastases
Phase 2UnknownLi-kun Chen542021-05-012021-07-27

Conditions studied

Brain Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Meningeal Carcinomatosis (1)  ·  Recurrence (1)

Interventions

Bevacizumab (1)  ·  anlotinib (1)  ·  aumolertinib (1)

Countries

China (3)

Top investigators

Likun Chen (1)

Results publications

PMID 41326640